The system, which received 510(k) clearance from the U.S. Food and Drug Administration in March, is a growth-friendly solution for pediatric patients, younger than 10 years, with severe progressive spinal deformities associated with thoracic insufficiency syndrome. It provides an alternative to traditional growing rods.
A medical technology guidance from NICE encouraged the NHS to use the MAGEC system in children who suffer from early onset scoliosis. This was then followed by a published draft policy by NHS with a similar endorsement.
To date, the system has been used by more than 200 surgeons in 24 countries.
More Articles on Devices:
5 Key Results: LDR’s Mobi-C Artificial Disc Replacement vs. ACDF
FDA Clears AccelSPINE’s Next Generation Minimally Invasive Spine System
Global Medical Device Market to Grow at 6.2% Annually Until 2018
